4 documents

Read All
01:05 , Jan 29, 2010 |  BC Extra  |  Top Story

Sinovac raises $57.5 million

Sinovac Biotech Ltd. (NASDAQ:SVA) raised $57.5 million through the sale of 10 million shares at $5.75 in a bumped-up follow-on underwritten by UBS and Piper Jaffray. Sinovac proposed to sell 8.7 million shares last week,...
Read More
01:02 , Jan 21, 2010 |  BC Extra  |  Financial News

Sinovac proposes follow-on

Sinovac Biotech Ltd. (NASDAQ:SVA) proposed late Wednesday to sell 8.7 million shares in a follow-on underwritten by UBS and Piper Jaffray. If sold at Sinovac's Wednesday close of $7.51, the company would raise $65 million....
Read More
07:00 , Apr 4, 2005 |  BC Week In Review  |  Company News

Sinovac sales and marketing update

SVA launched its Bilive vaccine to prevent hepatitis A and B infection in China. Sinovac Biotech Ltd. (SVA), Beijing, China   Business: Infectious   ...
Read More
08:00 , Jan 17, 2005 |  BC Week In Review  |  Clinical News

Bilive regulatory update

SVA received Chinese marketing and sales approval for Bilive, a combined hepatitis A & B vaccine. Sinovac Biotech Ltd. (SVA), Beijing, China   Product: Bilive   Business: Infectious   ...
Read More